



ASX Announcement

Section 708A Cleansing Statement

Melbourne, Australia; 28 October 2021:

This notice is given by Lumos Diagnostics Limited Ltd (ASX: LDX) (**Company**) under Section 708A(5)(e) of the *Corporations Action 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

- (a) It has today issued:
 - a. 120,000 Fully Paid Ordinary Shares at an issue price of \$1.25 per share to an entity associated with a director of the Company;
 - b. 24,000 Fully Paid Ordinary Shares at an issue price of \$1.25 per share to a director of the Company; and,
 - c. 130,577 Fully Paid Ordinary Shares at an issue price of \$1.25 to a number of employees of the Company.
- (b) the Shares referred to in paragraph (a) above were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) section 674 of the Corporations Act as it applies to the Company; and
- (e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

<ENDS>

This announcement has been approved by the Lumos Disclosure Committee.

###

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information on Lumos Diagnostics, visit lumosdiagnostics.com, and for more information on CovidDx, visit <https://lumosdiagnostics.com/products/covidx/>



Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts (U.S. and Global):

Jennifer Christiansen – Lumos Diagnostics

jennifer.christiansen@lumosdiagnostics.com

+1 920 784 3153

Media Contact (Australia):

Haley Chartres – H[^]CK

haley@hck.digital

+61 423 139 163

Investor Contact:

Matthijs Smith – Lumos Diagnostics

ir@lumosdiagnostics.com

+61 411 137 080

+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd

Level 4, 100 Albert Rd

South Melbourne, VIC 3205

+61 3 9087 1598